Novartis Expects Further Profit, Growth After Key Drugs Boost Sales

 Novartis expects profit and sales to grow further this year after beating analysts' expectations in the fourth quarter, boosted by revenue from its key drugs.

The Swiss pharma major said Friday that it expects its core operating profit--one of its preferred metrics, which strips out exceptional items--for 2025 to grow in the high-single-digit to low-double-digit range on sales growth in the mid- to high-single digits at constant currency.

Core operating profit for the fourth quarter grew to $4.86 billion from $3.82 billion for the same period the year prior on sales that increased to $13.15 billion from $11.42 billion. Analysts polled by Visible Alpha had forecast $4.44 billion in core operating profit on $12.78 billion in sales.

Net profit rose to $2.82 billion from $2.64 billion.

https://www.morningstar.com/news/dow-jones/202501311165/novartis-expects-further-profit-growth-after-key-drugs-boost-sales